Video

Dr. Wong on Anti-Amyloid Fibril Treatments in AL Amyloidosis

Author(s):

Sandy Wong, MD

In Partnership With:

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

Sandy Wong, MD, assistant professor, University of California, San Francisco School of Medicine, discusses anti-amyloid fibril treatments, a class of agents that have yet to receive FDA approval in the treatment of patients with immunoglobulin light chain amyloidosis (AL amyloidosis).

The NEOD001 agent has received a lot of attention over the past couple years. It is an anti-amyloid fibril monoclonal antibody that works against the amyloid fibrils to clean up the amyloid deposits in the body, allowing for organ recovery.

Early-phase studies reveal that it was well-tolerated in a first-in-human study of 27 patients with AL amyloidosis. The phase I trial, published in the Journal of Clinical Oncology, detailed a promising safety profile. Preliminary data also showed cardiac, renal, and neurologic responses.

The other anti-amyloid fibril therapy is CAEL-101. Data presented at the 2017 ASH Annual Meeting suggested that this drug looks similar to NEOD001 with regard to efficacy and safety.

Related Videos
J. Bradley Elder, MD
Rimas V. Lukas, MD
Shubham Pant, MD, MBBS
Brett L. Ecker, MD
Benjamin Garmezy, MD, assistant director, Genitourinary Research, Sarah Cannon Research Institute
Howard S. Hochster, MD, FACP,
John H. Strickler, MD
Brandon G. Smaglo, MD, FACP
Cedric Pobel, MD
Ruth M. O’Regan, MD
Related Content
Jairam Krishnamurthy, MD, FACP
November 22nd 2024

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

Jennie W. Taylor, MD, MPH, associate professor, clinical neurology, University of California, San Francisco, community engagement liaison, Neurologic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center
October 10th 2024

FDA Approval Insights: Vorasidenib in IDH1/2+ Grade 2 Astrocytoma and Oligodendroglioma

Here is your snapshot of all therapeutic options that the FDA approved in October 2024.
November 5th 2024

OncLive’s October Roundup of Key FDA Approvals in Oncology

Stephanie L. Graff, MD, director, Breast Oncology, Lifespan Cancer Institute, associate professor, medicine, Brown University; Reshma L. Mahtani, DO, medical oncologist, Miami Cancer Institute, chief, Breast Medical Oncology, Baptist Health’s Wellness and Medical Complex; Kelly E. McCann, MD, PhD, breast medical oncologist, assistant clinical professor, medicine, the University of California, Los Angeles Health David Geffen School of Medicine; Hope S. Rugo, MD, Winterhof Family Endowed Professor in Breast Cancer, the University of California San Francisco (UCSF), professor, medicine, Division of Hematology and Oncology, director, Breast Oncology, director, Clinical Trials Education, director, Cancer Infusion Services, the UCSF Helen Diller Family Comprehensive Cancer Center
April 11th 2024

Breast Cancer Experts Share Obstacles and Successes as Women in Oncology

Hope Rugo, MD, FASCO, of UCSF Helen Diller Family Comprehensive Cancer Center
October 31st 2024

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

Jeff Patton, MD
September 24th 2024

Medicare Drug Price Negotiations Will Have Domino Effect for Community Oncology Practices